RESEARCH



The mediating effect of sleep disturbance on the association between hypertension and depression: a national data analysis



Kamaluddin Latief^{1,2}, Samuel Akyirem³, Siriluk Sithichoksakulchai^{4,5}, Dieta Nurrika^{6,7}, Mokh. Sujarwadi⁸ and Faizul Hasan^{9*}[®]

Abstract

Background Sleep disturbance is a common among people with hypertension. However, the mediating role of sleep disturbance in the association between hypertension and depression remains unclear. This study aims to investigate the mediating role of sleep disturbance in the association between hypertension and depression.

Materials and methods This was cross-sectional study. The data were derived from the Indonesian Family Life Survey Fifth Wave (2014–2015). We include a total of 19,138 adults' participants with age range from 18 to 65 years old who completed response on the variable of hypertension, sleep disturbance, and depression. The mediating model analysis was processed using the PROCESS macro ins SPSS from Hayes model.

Results Depression was reported by 22% of total respondents. The group with hypertension showed a substantially higher prevalence of depression than non-hypertension group (P < 0.001). Hypertension had a significant overall effect on depression ($\beta = 0.682$; 95%Cl 0.489 to 0.875, P < 0.001). The direct effect of hypertension on depression was significant ($\beta = 0.418$; 95%Cl 0.244 to 0.592, P < 0.001) and the indirect effect that mediated by sleep disturbance was also significant ($\beta = 0.264$, 95%Cl 0.174 to 0.356, P < 0.001). It is worth noting that sleep disturbance partially mediated the association between hypertension and depression.

Conclusion The findings of this study indicated that sleep disturbance contributed to the etiology of depression and hypertension in adult populations. Nurses should be involved in managing sleep disturbances, such as using behavioral therapy, as it may serve as both a treatment and primary prevention measure for depression and hypertension.

Keywords Sleep, Depression, Nursing home care, Nurse observation, Nurse roles, Nurse practitioners, Nurse-patient interaction, Neurology, Mental health, Medical nursing

*Correspondence: Faizul Hasan faizulhasan89.fh@gmail.com; Faizul.h@chula.ac.th Full list of author information is available at the end of the article



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.gr/licenses/by/4.00. The Creative Commons Public Domain Dedication waiver (http://creativecommons.gr/licenses/by/4.00. The Creative Commons Public Domain Dedicated in a credit line to the data.



Background

Hypertension is a common chronic condition with global prevalence ranging from 31 to 56% [1, 2]. In Indonesia, about 8.4% of adults have been diagnosed with hypertension by a medical doctor [3]. Hypertension has been linked to elevated risk of cardiovascular comorbidities including stroke [4] and chronic kidney diseases [5, 6]. Other evidence suggests that people with hypertension are more likely to experience depression [7, 8].

Several studies have reported prevalence rates ranging from 22 to 32% [7, 9]. Previous studies suggest a bidirectional association between hypertension and depression [9, 10]. Depression may increase the risk of hypertension by activating the body's stress responses and increasing autonomic nervous system activation [11]. On the other hand, hypertension may increase the risk for depression by causing cerebrovascular pathologies [12] and increasing the sense of hopelessness related to living with a chronic condition [13]. People who suffer from both depression and hypertension often report low quality of life [14]. In addition, they often experience sleep disturbances [15]. While, the underlying mechanism of the hypertension-depression relationship remain complex, sleep disturbance has been identified as a potential mediator [15].

Sleep disturbance has been linked to physical and mental health including cardiovascular disease and mood disorders [16]. People with sleep problem have high risk to develop hypertension [17] and depression [18]. However, there is a lack of study investigating the mediating role of sleep disturbance in the association between hypertension and depression. Hence, in this study we aim to investigate the mediating role of sleep disturbance in the association between hypertension and depression using nationally representative data from Indonesia.

Materials and methods

Data source and participants

The data was derived from Indonesian Family Life Survey (IFLS) fifth Wave (IFLS-5), which is a cross-sectional study, fielded in September 2014 to April 2015. The IFLS sample represents approximately 83% of the Indonesian population living in 13 of the country's 26 provinces, covering 16,204 households and 50,148 individuals [19]. The IFLS has been conducted 5 times, in 1993, 1997, 2000, 2007, and 2014. The details of study design of the IFLS-5 have been previously described [19]. In this study, we include a total of 19,138 adults' participants with age range from 18 to 65 years old who have completed response on the variable of hypertension, sleep disturbance, and depression.

Ethical approval

The IFLS data are accessible to the general public. Institutional review boards at the University of Gajah Mada in Indonesia and the RAND Corporation in the United States have examined and approved the survey's methods with the ethical clearance No.s0064-06-01-CR01 [19]. Before data collection began, all participants provided their written, informed consent.

Measurements

Depression

Depression was measured using the short form Centres for Epidemiologic Studies Depression Scale (CES-D-10) [20]. CES-D-10 consist of 10 items rated on a 4-point Likert scale ranging from 0 (rarely or none of the time) to 3 (all of the time) with higher score indicating more depressive symptoms. A total score of 10 or higher is indicative of having depression. Previous study revealed that this scale has acceptable validity and reliability [19].

Hypertension

Previous studies using IFLS data indicate that hypertension, as measured by blood pressure, covers approximately 40% of participants [21, 22], while hypertension using self-reported measurements covers around 80% of participants [21]. Therefore, in this study, hypertension was assessed using self-report, measured with the question, "Has a doctor, paramedic, or nurse ever told you that you had hypertension?".

Sleep disturbance

Sleep disturbance was measured using the combination of five items of Patient-Reported Outcomes Measurement Information System (PROMIS) sleep disturbance measure [23] and five items of PROMIS sleep impairment measure [24]. Previous study reported that the scale has good Cronbach's alpha of 0.82 [25]. Higher scores on the scales indicate more sleep disturbance with a cut-off point 11 or higher indicating of having sleep disturbance [25].

Lifestyle and comorbidity condition

Smoking status was measured and classified into three groups (never, quitters and current tobacco users) [19]. Physical activity was measured using the short version of International Physical Activity Questionnaire (IPAQ) for the last 7 days (IPAQ-S7S) [26]. It is divided into three level of low, moderate, and high intensity physical activity. Additionally, for the outpatient care were assessed using single item questionnaire [19].

For comorbidity conditions (diabetes mellitus, tuberculosis, asthma, lung condition, heart attack, liver disease, stroke, cancer, high cholesterol, kidney disease, stomach or other digestive disease, and psychiatric problem). It was measured using single item question such as 'Has a doctor/paramedic/nurse/midwife ever told you that you had...? to which participants answered "yes" or "no" [19].

Demographic

In addition, demographic variable including age, gender, marital status, attending school, and education level were added in this study [19].

Statistical analyses

At the beginning, we used STATA software for all data processing. In the second stage, we used SPSS software version 29.0 to perform all statistical analyses (IBM, Armonk, NY, USA). A two-tailed of P < 0.05 was considered as a statistically significant level. To analyse the differences in the baseline characteristics between the 2 groups, we used the chi-squared or Fisher's exact test for categorical variables and independent t-tests for continuous variables. The correlation between main variable (hypertension, sleep disturbance, and depression) were measured using Pearson and Spearman correlation. Univariate and multivariate linear regression analyses were also performed. Finally, the mediating model analysis was processed using the PROCESS macro ins SPSS from Hayes model [27].

Result

Study characteristic

Figure 1 depicted the participants' flow diagram. In total, there were 25,824 adult participants were screened for eligibility. Of these, a total of 6,686 participants were excluded, with 779 not responding to questionnaires and 5,907 having missing data. This included missing data in the 'hypertension' variable (n=4,932), 'depression' variable (n=966), and 'sleep disturbance' variable (n=9). Finally, a total of 19,138 participants were included in the main analysis. Hypertension was confirmed for 2,736 (14.3%) individuals.

Demographic comparisons between patients with hypertension (n=2,736) and without hypertension (n=16,402) were presented in Table 1. The prevalence of hypertension varies across age groups, with rates of 6.5% for the 18–34 age group, 13.1% for the 35–49 age group, and 25.9% for the 50–65 age group. Most of the participants were married (84%) and 96% of them have attended the school.

The comparison of lifestyle and comorbidity conditions were presented in Table 2. In total 37% of included participants were smoker. The hypertension group had higher sleep disturbance compared to the non-hypertension group. There is a significant difference between the two groups in terms of physical activity (vigorous and low activity levels) (P<0.001 and P=0.001, respectively). Other details of the variable can be seen in Table 2.

Depression

The depression was reported in 22% of the total sample. The group with hypertension had a significantly higher depression prevalence compared to the non-hypertension group (see Table 2, P<0.001). Supplementary Table S1 presented the response of participants who endorse each of the depression questionnaires.



Fig. 1 Participant flow chart. *n* = number of participants

Tak	ble	1	Demograp	hic cor	nparison	of	participants
-----	-----	---	----------	---------	----------	----	--------------

Variables	Total (n = 19,138)		Missing data		Hypertension (n=2736)		No hypertension (n=16,402)		<i>p</i> -value
	n	(%)	n	(%)	n	(%)	n	(%)	
Age									< 0.001
18-34 years	6410	(33.5)			418	(15.3)	5992	(36.5)	
35–49 years	7635	(39.9)			998	(36.5)	6637	(40.5)	
50-65 years	5093	(26.6)			1320	(48.2)	3773	(23)	
Gender			1	(0.0)					< 0.001
Female	10,469	(54.7)			1817	(66.4)	8652	(52.7)	
Male	8668	(45.3)			919	(33.6)	7749	(47.2)	
Marital status			4	(0.0)					< 0.001 ^a
Single	1355	(7.1)			81	(3)	1274	(7.8)	
Married	16,058	(83.9)			2263	(82.7)	13,795	(84.1)	
Separated	102	(0.5)			12	(0.4)	90	(0.5)	
Divorced	487	(2.5)			68	(2.5)	419	(2.6)	
Windowed	1128	(5.9)			310	(11.3)	818	(5)	
Cohabitate	4	(0.0)			2	(0.1)	4	(0.0)	
Have you ever attended/ are you attending school?			2	(0.0)					< 0.001
Yes	18,365	(96)			2571	(94)	15,794	(96.3)	
No	771	(4)			165	(6)	606	(3.7)	
Education level			773	(4)					< 0.001
University level	1891	(9.9)			220	(8)	1671	(10.2)	
Below university level	17,247	(90.1)			2516	(92)	14,731	(89.8)	

Continuous variable was performed by using independent t-test,

Categorical variables were performed by using chi-square test or ^aFisher's exact test

n (%) n (%) n (%) n (%) Sinoking 7060 63.69 74.8 (7.2) 63.17 (38.5) No 120/2 (63.1) 1998 (7.2) (10.05 (61.5) Sileep statubance	Variables	Total (<i>n</i> = 19,138)		Missing data		Hypertension (n=2736)		No hypertension (n=16,402)		<i>p</i> -value
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		n	(%)	n	(%)	n	(%)	n	(%)	
Yes748(7.3)6.317(48.5)No12.023(6.1)1988(7.2)10.08(6.1)Step distribuce(7.1)2.75(1.7)No16.415(8.50)2.268(8.2)(1.4)(6.3)Depression(7.3)(7.3)(7.3)Wis40.66(1.3)6.73(7.4)3.89(2.0)No15.70(7.7)(7.5)(7.3)(7.3)(7.3)Physical activity during last 7-lays(7.3)(7.3)(7.3)(7.3)Wis41.62(7.2)444(1.7)3.732(2.2)No15.70(7.3)2.72(7.3)(7.3)(7.3)Wis11.922(7.8)2.72(7.3)(7.3)(7.3)No8230(3.7)1549(6.6)9.359(7.1)No8230(3.3)1.167(4.3)10.6(4.2)No13.745(7.0)2.72(2.6)(3.4)1.56(0.0)No13.745(7.8)2.001.566(9.3)(2.0)No13.741(9.3)1.607(7.4)(7.4)(7.4)No13.741(9.3)1.608(3.1)(4.8)(3.6)No13.600(7.2)2.73(7.3)(7.4)(7.4)No13.600(7.2)2.73(9.5)(9.6)(7.4)No13.600(7.2)2.73(9.5) <t< td=""><td>Smokina</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>< 0.001</td></t<>	Smokina									< 0.001
No12,073(6.1)1998(7.2)10,085(6.1)Sice platurbance	Yes	7065	(36.9)			748	(27.3)	6317	(38.5)	
Sleep disturbance , , , , , , , , , , , , , , , , , , ,	No	12,073	(63.1)			1988	(72.7)	10,085	(61.5)	
Yes273(142)468(17.)2255(13.7)No16.45(8.8)2208(2.9)1.4(8.6.3)Depression(2.13)6.79(4.6)3.89(0.7)Yes15.07(7.8)2357(7.9)3.89(7.9)Phycal activity during last / Jarren with the second activity	Sleep disturbance	,						.,		< 0.001
<table-container>No16,415(85.8)2688(82.9)14,147(86.3) (80.0)Depresion(78.7)67.9(78.3)(78.1)(78.1)(78.1)(78.1)No15,070(78.7)2057(75.2)13,013(78.1)(78.1)Physical activity during lax 7 arrs(78.2)(78.2)(78.2)(78.2)(78.2)(78.2)(78.2)No421.6(22)48.4(17.7)37.52(22.8)(78.2)<td>Yes</td><td>2723</td><td>(14.2)</td><td></td><td></td><td>468</td><td>(17.1)</td><td>2255</td><td>(13.7)</td><td></td></table-container>	Yes	2723	(14.2)			468	(17.1)	2255	(13.7)	
Depression <	No	16.415	(85.8)			2268	(82.9)	14,147	(86.3)	
''Pes4068(21.3)679(24.8)3389(20.7)No15,070(75,7)(75,2)13,013(79.3)Physical activities	Depression	., .	(*****)				(,	,	(*****)	< 0.001
No15.070(78.7)2057(75.2)13.013(79.3)Physical activity during lact Vity<	Yes	4068	(21.3)			679	(24.8)	3389	(20.7)	
Physical activity during last 7 data initial activity during last 7 data initial activity during last 7 data Physical activity during last 7 data initial data initial data initial data Yes 4216 (22) 484 (17.7) 3732 (22.6) No 14.922 (78) 1549 (56.6) 9359 (57.1) Moderate activities	No	15.070	(78.7)			2057	(75.2)	13.013	(79.3)	
Vigorul activities (2001) Vigorul activities (22) 484 (17,7) 3732 (2,8) Moderate activities	Physical activity during last	7 davs	(,				(* • • =)	,	(,	
New4216(22)484(17.7)3732(22.8)No14.922(78)2252(82.3)12.670(77.2)Moderate activitiesVes0.008(57)1549(65.6)959(57.1)No8230(43)1187(43.4)7043(42.9)Low activitiesVes15.45(70.8)2009(73.4)11.536(70.3)No5593(29.2)No5593(70.8)2009(73.4)11.536(70.6)Did you have outlestVes15.414(19.4)86.8(31.7)284.8(17.4)Yes13.64(80.5)OctorotidyYes18.7(19.4)No18.7(19.1)No18.7(19.1)No18.7(17.1)No18.7(17.1)No18.7(19.1)No18.7 <t< td=""><td>Vigorous activities</td><td>, ddys</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>< 0.001</td></t<>	Vigorous activities	, ddys								< 0.001
No 1.4.0 1.1.1 1.1.1 1.1.2 1.1.2 1.1.2 No 1.4.922 (78) 252 (82.3) 12.6.70 (77.2) Moderate activities 571 1549 (56.6) 9359 (57.1) No 13.545 (70.8) 200 (73.4) 11.536 (70.3) Low activities	Yes	4216	(22)			484	(177)	3732	(22.8)	0.001
Inter Problem	No	14 977	(22)			2252	(82.3)	12 670	(22.0)	
None 10,08 (57) 1549 (56) 9359 (57) No 8230 (43) 1187 (43,4) 7043 (429) Low activities .	Moderate activities	11,722	(70)			LLJL	(02.5)	12,070	(77.2)	0.68
IAG IAG <thiag< th=""> <thiag< th=""> <thiag< th=""></thiag<></thiag<></thiag<>	Yes	10 908	(57)			1549	(56.6)	9359	(57.1)	0.00
Low activities no issue	No	8230	(13)			1187	(33.0)	7043	(12.0)	
Yes 13,545 (70.8) 2009 (73.4) 11,536 (70.3) No 5593 (29.2) 727 (26.6) 4866 (29.7) Did you have outpatient care last 4 weeks? 8 (0.0) 226.8 4866 (29.7) Yes 3716 (19.4) 868 (31.7) 2848 (17.4) No 15,414 (80.5) 1868 (68.3) 13,546 (82.6) Comorbidity T 1868 (68.3) 13,546 (82.6) (90.1) No 15,610 (92.1) 2503 (91.5) 16,097 (98.1) No 18,600 (97.2) 2503 (91.5) 16,097 (98.1) Yes 538 (2.8) 2705 (98.9) 16,264 (99.1) Yes 187 (1.1) 156 (1.1) (91.1) (91.1) (91.1) No 18,050 (97.3) 2618 (95.7) 16,463 (92.1) No	Low activities	0250	(15)			1107	(15.1)	7015	(12.5)	0.001
Ins 15,593 (7,00) 2009 (7,37) (7,130) (7,03) No 5593 (29,2) 727 (26,6) 4866 (29,7) Lid you have outpatient care last 4 weeks? 8 (0,0) 2009 (3,5) 2848 (7,4) Yes 3716 (19,4) 868 (68,3) 13,546 (82,6) Comorbidity E 15,414 (80,5) 2848 (1,7) Pas 5380 (2,8) 233 (8,5) 305 (1,9) No 18,60 (9,7) 2019 2055 (98,9) 16,097 (8,1) Tuberculosis I 11 11 156 (1,9) (1,0) (2,0) (1,0) (1,0) (1,0) (1,0) <	Voc	12545	(70.9)			2000	(72 /)	11 526	(70.2)	0.001
Ind Jos Les Res Les Les Coult Didyou have outpatient care last 4 weeks? 8 (0.0)	No	5502	(70.0)			2009	(73.4)	11,550	(70.3)	
Total part of the set	Did you have outpatient	2292	(29.2)	0	(0,0)	121	(20.0)	4800	(29.7)	< 0.001
Yes 3716 (194) 868 (31.7) 2848 (17.4) No 15414 (80.5) 1868 (68.3) 13,546 (82.6) Comorbidity Diabetes mellites <	care last 4 weeks?			ŏ	(0.0)					< 0.001
No 15,41 (80.5) 1868 (68.3) 13,546 (82.6) Comordidity Diabetes mellites <	Yes	3716	(19.4)			868	(31.7)	2848	(17.4)	
Construction of the set of the	No	15,414	(80.5)			1868	(68.3)	13,546	(82.6)	
Diabetes mellites < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <	Comorbidity									
Yes 538 (2.8) 233 (8.5) 305 (1.9) No 18,600 (97.2) 2503 (91.5) 16,097 (98.1) Tuberculosis 11 31 (1.1) 156 (1) No 18,951 (97.2) 31 (1.1) 156 (1) No 18,951 (97.3) 2618 (9.3) 16,097 (97.6) Asthma (2.7) 118 (4.3) 35.0 (2.4) No 18,625 (97.3) 2618 (95.7) 16,007 (97.6) Other lung condition 18,626 (97.3) 2684 (98.1) 16,122 (98.3) Yes 332 (1.7) 52 (1.9) 28.0 (1.7) No 18,806 (98.3) 2684 (98.1) 16,122 (98.3) Yes 384 (2) 2583 (94.4) 16,171 (98.6) Iver disease	Diabetes mellites									< 0.001
No 18,600 (97.2) 2503 (91.5) 16,097 (98.1) Tuberculosis	Yes	538	(2.8)			233	(8.5)	305	(1.9)	
Tuberculosis 0.35 Yes 187 (1) 31 (1.1) 156 (1) No 18,951 (99) 2705 (98.9) 16,246 (99) Asthma	No	18,600	(97.2)			2503	(91.5)	16,097	(98.1)	
Yes 187 (1) 31 (1.1) 156 (1) No 18,951 (99) 2705 (98.9) 16,246 (99) Asthma <td< td=""><td>Tuberculosis</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.35</td></td<>	Tuberculosis									0.35
No 18,951 (99) 2705 (98.9) 16,246 (99) Asthma <td>Yes</td> <td>187</td> <td>(1)</td> <td></td> <td></td> <td>31</td> <td>(1.1)</td> <td>156</td> <td>(1)</td> <td></td>	Yes	187	(1)			31	(1.1)	156	(1)	
Asthma	No	18,951	(99)			2705	(98.9)	16,246	(99)	
Yes 513 (2.7) 118 (4.3) 395 (2.4) No 18,625 (97.3) 2618 (95.7) 16,007 (97.6) Other lung condition 52 (1.9) 280 (1.7) 0.48 Yes 332 (1.7) 52 (1.9) 280 (1.7) No 18,806 (98.3) 2684 (98.1) 16,122 (98.3) Heart attack	Asthma									< 0.001
No 18,625 (97.3) 2618 (95.7) 16,007 (97.6) Other lung condition . <td< td=""><td>Yes</td><td>513</td><td>(2.7)</td><td></td><td></td><td>118</td><td>(4.3)</td><td>395</td><td>(2.4)</td><td></td></td<>	Yes	513	(2.7)			118	(4.3)	395	(2.4)	
Other lung condition 0.48 Yes 332 (1.7) 52 (1.9) 280 (1.7) No 18,806 (98.3) 2684 (98.1) 16,122 (98.3) Heart attack	No	18,625	(97.3)			2618	(95.7)	16,007	(97.6)	
Yes332(1.7)52(1.9)280(1.7)No18,806(98.3)2684(98.1)16,122(98.3)Heart attack53(5.6)231(1.4)Yes384(2)153(5.6)231(1.4)No18,754(98.9)2583(94.4)16,171(98.6)Liver disease55(0.9)176(1.1)No18,937(98.9)2711(99.1)16,263(98.9)Stroke2541(96.5)16,362(98.9)Yes135(0.7)95(3.5)40(0.2)No19,003(99.3)2641(96.5)16,362(99.8)Cancer140(0.7)31(1.1)109(0.7)	Other lung condition									0.48
No 18,806 (98.3) 2684 (98.1) 16,122 (98.3) Heart attack - - <	Yes	332	(1.7)			52	(1.9)	280	(1.7)	
Heart attack	No	18,806	(98.3)			2684	(98.1)	16,122	(98.3)	
Yes384(2)153(5.6)231(1.4)No18,754(98)2583(94.4)16,171(98.6)Liver disease2583(0.9)176(1.1)No18,937(98.9)2711(99.1)16,226(98.9)Stroke </td <td>Heart attack</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>< 0.001</td>	Heart attack									< 0.001
No 18,754 (98) 2583 (94.4) 16,171 (98.6) Liver disease 0.54 Yes 201 (1.1) 25 (0.9) 176 (1.1) No 18,937 (98.9) 2711 (99.1) 16,226 (98.9) Stroke (0.7)	Yes	384	(2)			153	(5.6)	231	(1.4)	
Liver disease 0.54 Yes 201 (1.1) 25 (0.9) 176 (1.1) No 18,937 (98.9) 2711 (99.1) 16,226 (98.9) Stroke	No	18,754	(98)			2583	(94.4)	16,171	(98.6)	
Yes201(1.1)25(0.9)176(1.1)No18,937(98.9)2711(99.1)16,226(98.9)Stroke </td <td>Liver disease</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>0.54</td>	Liver disease									0.54
No 18,937 (98.9) 2711 (99.1) 16,226 (98.9) Stroke	Yes	201	(1.1)			25	(0.9)	176	(1.1)	
Stroke <	No	18,937	(98.9)			2711	(99.1)	16,226	(98.9)	
Yes135(0.7)95(3.5)40(0.2)No19,003(99.3)2641(96.5)16,362(99.8)Cancer0.01Yes140(0.7)31(1.1)109(0.7)	Stroke									< 0.001
No 19,003 (99.3) 2641 (96.5) 16,362 (99.8) Cancer 0.01 Yes 140 (0.7) 31 (1.1) 109 (0.7)	Yes	135	(0.7)			95	(3.5)	40	(0.2)	
Cancer 0.01 Yes 140 (0.7) 31 (1.1) 109 (0.7)	No	19,003	(99.3)			2641	(96.5)	16,362	(99.8)	
Yes 140 (0.7) 31 (1.1) 109 (0.7)	Cancer									0.01
	Yes	140	(0.7)			31	(1.1)	109	(0.7)	
No 18,998 (99.3) 2705 (98.9) 16,293 (99.3)	No	18,998	(99.3)			2705	(98.9)	16,293	(99.3)	

Table 2 Lifestyle and comorbid comparison of participants

Variables	Total (<i>n</i> = 19,138)		Missing data		Hypertension (n=2736)		No hypertension (n=16,402)		<i>p</i> -value
	n	(%)	n	(%)	n	(%)	n	(%)	
High cholesterol									< 0.001
Yes	1031	(5.4)			438	(16)	593	(3.6)	
No	18,107	(94.6)			2298	(84)	15,809	(96.4)	
Kidney disease									< 0.001
Yes	303	(1.6)			83	(3)	220	(1.3)	
No	18,835	(98.4)			2653	(97)	16,182	(98.7)	
Stomach or other dige	estive disease								< 0.001
Yes	2499	(13.1)			503	(18.4)	1996	(12.2)	
No	16,639	(86.9)			2233	(81.6)	14,406	(87.8)	
Psychiatric problem									0.04
Yes	32	(0.2)			9	(0.3)	23	(0.1)	
No	19,106	(99.8)			2727	(99.7)	16,379	(99.9)	

Categorical variables were performed by using chi-square test

Association between the hypertension, sleep disturbance, and depression

Supplementary Table S2 shows the association between the hypertension, sleep disturbance, and depression. The hypertension variable had a significant positive correlation with depression (r = 0.05, P < 0.001). The hypertension variable also has a significant positive correlation with sleep disturbance (r = 0.05, P < 0.001). Similarly sleep disturbance variable also has a significant positive correlation with depression (r = 0.44, P < 0.001).

The bivariate and multiple linear regression results are displayed in Table 3. In the unadjusted model, all predictors show a significant positive association with the target variable. When hypertension and sleep disturbance are combined as predictors in Model 1, the association remains significantly positive. In Model 2, all predictors also exhibit a significant positive association with the outcome variables.

Mediating effect of sleep disturbance on the association between hypertension and depression

The simple mediating analysis indicated that sleep disturbance partially mediated the association between hypertension and depression. As shown in Fig. 2 and supplementary Table 3, hypertension was positively associated with sleep disturbance (a=0.725), and sleep disturbance was positively associated with depression (b=0.364). Based on 5,000 bootstrap resamples, the bootstrap confidence interval for the indirect effect (ab = 0.264) was entirely above zero, ranging from 0.174 to 0.356. The total effect of hypertension on depression was significant (β =0.682; 95% CI 0.489 to 0.875, P < 0.001), comprising a direct effect ($\beta = 0.418$; 95% CI 0.244 to 0.592, P < 0.001) and an indirect effect ($\beta = 0.264$; 95% CI 0.174 to 0.356, *P* < 0.001).

Discussion

To the best of our knowledge, this is the first study investigating the mediating effect of sleep disturbance in the association between hypertension and depression. This study highlights that sleep disturbance becomes partial mediation in the association between hypertension and depression. Because the methodology is rigorous and we use a big sample size, hence our study should be considered.

		C 1.1 1 11				1 1. 1	
12610 2	Accociations	trom multiple lipes	rogroccion	models of h	inortoncion with	a cloop dicturbance	and donroccion
LAUIP 5	ASSOCIATIONS	IIOIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	TECHESSION		/	I SIEED UISTUDATICE	
	7.0500000000000	month manapic micui	regression		percension mic	i sicep distandunce	, and acpression

Predictor	Target variable	Unadjusted					Model 1			Model 2
		βª	βs	(95% CIs)	βª	βs	(95% CIs)	βª	βs	(95% Cls)
Hypertension	Depression	0.68	0.05	(0.49 to 0.88)	0.94	0.07	(0.79 to 1.19)	0.60	0.04	(0.40 to 0.80)
Hypertension	Sleep disturbance	0.73	0.05	(0.49 to 0.96)	0.88	0.05	(0.68 to 1.17)	0.50	0.03	(0.27 to 0.73)
Hypertension	Depression	0.42	0.03	(0.24 to 0.59)	0.66	0.05	(0.47 to 0.84)	0.47	0.03	(0.29 to 0.66)
Sleep disturbance		0.36	0.43	(0.35 to 0.38)	0.37	0.43	(0.35 to 0.37)	0.37	0.44	(0.36 to 0.39)

model 1 = adjusted for variables in Table 1, model 2 = adjusted for variables in Tables 1 and 2

 β^a = Unstandardized coefficients, β^s = Standardized coefficients, CI = Confidence intervals



Fig. 2 Mediation Analysis Results. The data were presented in Beta coefficient (standard error)

Although the pathological mechanism of sleep disturbance after hypertension was complex. However, it can develop as a result of hypertension due to factors such as persistent physiological stress [28], increased sympathetic nervous system activity causing alertness [29, 30], disrupted nighttime blood pressure patterns [31], potential sleep-affecting medication side effects [32], psychological impact from hypertension management [33], and endothelial dysfunction [34, 35], all of which contribute to sleep disruptions. Effective hypertension treatment, lifestyle changes [36], and stress reduction measures are critical for sleep disturbance [37]. If sleep problems persist, it is critical to consult a healthcare practitioner, as treating hypertension may improve sleep quality [37–39].

In this study, sleep disturbance is observed in approximately 17% of the hypertension group and 13.7% of the non-hypertension group. Consistent with previous studies, sleep disturbances such as obstructive sleep apnea (OSA) and insomnia are prevalent following hypertension [32, 40, 41]. Evidence suggests that OSA becomes a significant risk factor for hypertension [42]. Numerous pathways, including endothelial impairment [43, 44], oxidative stress [45, 46], inflammation [47, 48], and sympathetic activation [49, 50], are generally acknowledged as ways in which OSA leads to the development of hypertension. Of note, this study reveals that sleep disturbance partially mediates the association between hypertension and depression. It indicates that targeting depression treatment after hypertension should also consider sleep disturbance.

We found that the prevalence of depression following hypertension in our study is 25% which is higher than in

the non-hypertension group (21%, see Table 2). In line with previous studies, the prevalence of depression was ranging from 22 to 32% following hypertension [7, 9] and 13–17% in the general population [51, 52]. Because the presence of depression affects the health-related quality of life [14]. Hence, it is important for clinicians and researchers to implement the best treatment approach for depression.

Strengths and limitations

To the best of our knowledge, this study possesses several strengths. First, this study was national representativeness of the data since the study population was taken from participants across Indonesia. Second, all interviewers for the IFLS were trained to understand the methodology and the content of the questionnaire.

This study highlights several limitations. First, the data related severity of hypertension, subtype, and type of medication is not available. Second, potential confounders could not obtain such use hypnotic used, dietary factors, and environmental factors, which may threaten the internal validity. Third, the data related to blood pressure and medication for hypertension is unable to be provided. Fourth, the data related to hypertension was selfreported, which may cause information bias.

Conclusion

The result of this study suggested that sleep disturbance plays a role in the etiology of hypertension and depression in adult populations. The management of sleep disturbance could potentially serve as treatment and primary prevention for depression in these populations. Behavioral therapy could be implemented to reduce sleep disturbance.

Abbreviations

IFLS	Indonesian Family Life Survey
CES-D-10	Centers for Epidemiologic Studies Depression Scale
PROMIS	Patient-Reported Outcomes Measurement Information System
IPAQ	International Physical Activity Questionnaire
OSA	Obstructive sleep apnea

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s40885-024-00263-y.

Additional file 1: Supplementary Table S1. Depression items: the percentages of participants who endorse each response (N = 19138).

Additional file 2: Supplementary Table S2. The correlation between main variables (*N* = 19138).

Additional file 3: Supplementary Table S3. Mediating analysis.

Acknowledgements

Not applicable.

Authors' contributions

FH and KL acquired data, performed the statistical analyses, interpreted data, and drafted and revised the manuscript for important intellectual content and approved the final version. SA, SS, DN, and MS interpreted data, reviewed the analyses, and approved the final version.

Funding

Not applicable.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

This study was approved by the Institutional review boards at the University of Gajah Mada in Indonesia and the RAND Corporation in the United States with the ethical clearance No. s0064-06-01-CR01.

Consent for publication

Not applicable.

Competing interests

The authors declare no potential conflicts of interest.

Author details

¹Global Health and Health Security, College of Public Health, Taipei Medical University, Taipei, Taiwan. ²Centre for Family Welfare, Faculty of Public Health, Universitas Indonesia, Depok, Indonesia. ³Yale School of Nursing, Yale University, New Haven, CT, USA. ⁴Department of Fundamental Nursing, Faculty of Nursing, Mahidol University, Bangkok, Thailand. ⁵College of Nursing, Kaohsiung Medical University, Kaohsiung, Taiwan. ⁶Public Health Study Program, Banten School of Health Science, South Tangerang, Indonesia. ⁷Culture, Research, and Technology, The Ministry of Education, Higher Education Service Institutions (LL-DIKTI) Region IV, Bandung, Indonesia. ⁸Faculty of Nursing, Universitas Jember, Jember, Indonesia. ⁹Faculty of Nursing, Chulalongkorn University, Boromarajonani Srisataphat Building, 12th Floor Rama1 Road, Wang Mai, Pathum Wan, Bangkok 10330, Thailand.

Received: 5 October 2023 Accepted: 10 January 2024 Published online: 01 February 2024

References

- Bloch MJ. Worldwide prevalence of hypertension exceeds 1.3 billion. J Am Soc Hypertens. 2016;10(10):753–4.
- Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004;22(1):11–9.
- 3. Kemenkes RI. Laporan Nasional Riset Kesehatan Dasar. Kementerian Kesehatan RI. 2018. p. 203.
- Wajngarten M, Silva GS. Hypertension and stroke: update on treatment. Eur Cardiol Rev. 2019;14(2):111.
- Faraco G, ladecola C. Hypertension: a harbinger of stroke and dementia. Hypertension. 2013;62(5):810–7.
- Lauder L, Mahfoud F, Azizi M, Bhatt DL, Ewen S, Kario K, et al. Hypertension management in patients with cardiovascular comorbidities. Eur Heart J. 2023;44(23):2066–77.
- Li Z, Li Y, Chen L, Chen P, Hu Y. Prevalence of depression in patients with hypertension: a systematic review and meta-analysis. Medicine. 2015;94:31.
- Villarreal-Zegarra D, Bernabe-Ortiz A. Association between arterial hypertension and depressive symptoms: results from population-based surveys in Peru. Asia-Pacific Psychiatry. 2020;12(2):e12385.
- Mai AS, Lim OZH, Ho YJ, Kong G, Lim GEH, Ng CH, et al. Prevalence, risk factors and intervention for depression and anxiety in pulmonary hypertension: a systematic review and meta-analysis. Front Med. 2022;9: 765461.
- Meng L, Chen D, Yang Y, Zheng Y, Hui R. Depression increases the risk of hypertension incidence: a meta-analysis of prospective cohort studies. J Hypertens. 2012;30(5):842–51.
- 11. Scalco AZ, Scalco MZ, Azul JBS, Neto FL. Hypertension and depression. Clinics. 2005;60(3):241–50.
- 12. Turana Y, Tengkawan J, Chia YC, Shin J, Chen CH, Park S, et al. Mental health problems and hypertension in the elderly: review from the HOPE Asia Network. J Clin Hypertens. 2021;23(3):504–12.
- Ang CW, Tan MM, Bärnighausen T, Reininghaus U, Reidpath D, Su TT. Mental distress along the cascade of care in managing hypertension. Sci Rep. 2022;12(1):15910.
- 14. Zhang Y, Zhou Z, Gao J, Wang D, Zhang Q, Zhou Z, et al. Health-related quality of life and its influencing factors for patients with hypertension: evidence from the urban and rural areas of Shaanxi Province, China. BMC Health Serv Res. 2016;16:1–9.
- Cai Y, Chen M, Zhai W, Wang C. Interaction between trouble sleeping and depression on hypertension in the NHANES 2005–2018. BMC Public Health. 2022;22(1):1–11.
- Seow LSE, Tan XW, Chong SA, Vaingankar JA, Abdin E, Shafie S, et al. Independent and combined associations of sleep duration and sleep quality with common physical and mental disorders: results from a multi-ethnic population-based study. PLoS One. 2020;15(7): e0235816.
- Vgontzas AN, Liao D, Bixler EO, Chrousos GP, Vela-Bueno A. Insomnia with objective short sleep duration is associated with a high risk for hypertension. Sleep. 2009;32(4):491–7.
- Kudlow P, Cha D, Lam R, McIntyre R. Sleep architecture variation: a mediator of metabolic disturbance in individuals with major depressive disorder. Sleep Med. 2013;14(10):943–9.
- Strauss J, Witoelar F, Sikoki B. The fifth wave of the Indonesia family life survey: overview and field report, Vol. 1. Santa Monica: Rand; 2016. p. 1–94.
- Knight RG, Williams S, McGee R, Olaman S. Psychometric properties of the centre for epidemiologic studies depression scale (CES-D) in a sample of women in middle life. Behav Res Ther. 1997;35(4):373–80.
- Mahwati Y, Nurrika D, Latief K. The determinants of undiagnosed hypertension among Indonesian adults: a cross-sectional study based on the 2014–2015 Indonesia family life survey. J Prev Med Public Health. 2022;55(1):60.
- 22. Latief K, Nurrika D, Tsai M-K, Gao W. Body mass index asian populations category and stroke and heart disease in the adult population: a longitudinal study of the Indonesia Family Life Survey (IFLS) 2007 and 2014. BMC Public Health. 2023;23(1):2221.

- 23. Yu L, Buysse DJ, Germain A, Moul DE, Stover A, Dodds NE, et al. Development of short forms from the PROMIS[™] sleep disturbance and sleeprelated impairment item banks. Behav Sleep Med. 2012;10(1):6–24.
- Buysse DJ, Yu L, Moul DE, Germain A, Stover A, Dodds NE, et al. Development and validation of patient-reported outcome measures for sleep disturbance and sleep-related impairments. Sleep. 2010;33(6):781–92.
- Peltzer K, Pengpid S. Prevalence, social and health correlates of insomnia among persons 15 years and older in Indonesia. Psychol Health Med. 2019;24(6):757–68.
- Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35(8):1381–95.
- Hayes AF. Mediation, moderation, and conditional process analysis. Introduction to mediation, moderation, and conditional process analysis: A regression-based approach, Vol. 1. 2013. p. 20.
- Kalmbach DA, Cuamatzi-Castelan AS, Tonnu CV, Tran KM, Anderson JR, Roth T, et al. Hyperarousal and sleep reactivity in insomnia: current insights. Nat Sci Sleep. 2018;10:193–201.
- Maes J, Verbraecken J, Willemen M, De Volder I, Van Gastel A, Michiels N, et al. Sleep misperception, EEG characteristics and autonomic nervous system activity in primary insomnia: a retrospective study on polysomnographic data. Int J Psychophysiol. 2014;91(3):163–71.
- Bonnet MH, Arand DL. Hyperarousal and insomnia: state of the science. Sleep Med Rev. 2010;14(1):9–15.
- Maiolino G, Bisogni V, Soranna D, Pengo MF, Pucci G, Vettor R, et al. Effects of insomnia and restless legs syndrome on sleep arterial blood pressure: a systematic review and meta-analysis. Sleep Med Rev. 2021;59: 101497.
- Jarrin DC, Alvaro PK, Bouchard M-A, Jarrin SD, Drake CL, Morin CM. Insomnia and hypertension: a systematic review. Sleep Med Rev. 2018;41:3–38.
- 33. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111(5):697–716.
- Portaluppi F, Tiseo R, Smolensky MH, Hermida RC, Ayala DE, Fabbian F. Circadian rhythms and cardiovascular health. Sleep Med Rev. 2012;16(2):151–66.
- Chen L, Yang G. Recent advances in circadian rhythms in cardiovascular system. Front Pharmacol. 2015;6:71.
- Williams B, Poulter N, Brown M, Davis M, McInnes G, Potter J, et al. Guidelines for management of hypertension: report of the fourth working party of the British hypertension society, 2004—BHS IV. J Hum Hypertens. 2004;18(3):139–85.
- Lytle J, Mwatha C, Davis KK. Effect of lavender aromatherapy on vital signs and perceived quality of sleep in the intermediate care unit: a pilot study. Am J Crit Care. 2014;23(1):24–9.
- Carnethon MR, Johnson DA. Sleep and resistant hypertension. Curr Hypertens Rep. 2019;21:1–6.
- Cho M-C. Clinical significance and therapeutic implication of nocturnal hypertension: relationship between nighttime blood pressure and quality of sleep. Korean Circ J. 2019;49(9):818–28.
- Thomas SJ, Calhoun D. Sleep, insomnia, and hypertension: current findings and future directions. J Am Soc Hypertens. 2017;11(2):122–9.
- Pepin J-L, Borel A-L, Tamisier R, Baguet J-P, Levy P, Dauvilliers Y. Hypertension and sleep: overview of a tight relationship. Sleep Med Rev. 2014;18(6):509–19.
- Kareem O, Tanvir M, Naqash A, Bader GN. Obstructive sleep Apnoea: a risk factor for hypertension. J Cardiol Cardiovasc Sci. 2018;2(2):20–8.
- Hirata Y, Nagata D, Suzuki E, Nishimatsu H, Suzuki J-i, Nagai R. Diagnosis and treatment of endothelial dysfunction in cardiovascular disease a review. Int Heart J. 2010;51(1):1–6.
- Jafari B, Mohsenin V. Endothelial dysfunction and hypertension in obstructive sleep apnea–Is it due to intermittent hypoxia? J Cardiovasc Disease Res. 2013;4(2):87–91.
- Lavie L. Oxidative stress in obstructive sleep apnea and intermittent hypoxia-revisited-the bad ugly and good: implications to the heart and brain. Sleep Med Rev. 2015;20:27–45.

- Eisele HJ, Markart P, Schulz R. Obstructive sleep apnea, oxidative stress, and cardiovascular disease: evidence from human studies. Oxid Med Cell Longev. 2015;2015.
- 47. Unnikrishnan D, Jun J, Polotsky V. Inflammation in sleep apnea: an update. Rev Endocr Metab Disord. 2015;16:25–34.
- Chul Sung K, Suh JY, Kim BS, Kang JH, Kim H, Lee MH, et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens. 2003;16(6):429–33.
- 49. Parati G, Lombardi C, Hedner J, Bonsignore MR, Grote L, Tkacova R, et al. Position paper on the management of patients with obstructive sleep apnea and hypertension: joint recommendations by the European Society of Hypertension, by the European Respiratory Society and by the members of European COST (COoperation in Scientific and Technological research) ACTION B26 on obstructive sleep apnea. J Hypertens. 2012;30(4):633–46.
- Freet CS, Stoner JF, Tang X. Baroreflex and chemoreflex controls of sympathetic activity following intermittent hypoxia. Auton Neurosci. 2013;174(1–2):8–14.
- Lim GY, Tam WW, Lu Y, Ho CS, Zhang MW, Ho RC. Prevalence of depression in the community from 30 countries between 1994 and 2014. Sci Rep. 2018;8(1):2861.
- 52. Alamri HS, Algarni A, Shehata SF, Al Bshabshe A, Alshehri NN, ALAsiri AM, et al. Prevalence of depression, anxiety, and stress among the general population in Saudi Arabia during Covid-19 pandemic. Int J Environ Res Public Health. 2020;17(24): 9183.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.